APA (7th ed.) Citation

Yan Liu, Yan Liu, Guanxing Zhai, Weihui Fu, Xiaoyan Zhang, Xiaoyan Zhang, . . . Jianqing Xu. (2022). A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Yan Liu, Yan Liu, Guanxing Zhai, Weihui Fu, Xiaoyan Zhang, Xiaoyan Zhang, Jianqing Xu, and Jianqing Xu. A Randomized, Double-blind, Placebo-controlled Phase I Trial of Inhalation Treatment of Recombinant TFF2-IFN Protein: A Multifunctional Candidate for the Treatment of COVID-19. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Yan Liu, et al. A Randomized, Double-blind, Placebo-controlled Phase I Trial of Inhalation Treatment of Recombinant TFF2-IFN Protein: A Multifunctional Candidate for the Treatment of COVID-19. Frontiers Media S.A., 2022.